Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing

PURPOSE: Given regulatory approval of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D) cancers agnostic to tumor type, it has become important to characterize occurrence of MMR-D and develop cost-effective screening approaches. Using a next-generation sequencing (NGS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Albayrak, Adem, Garrido-Castro, Ana C., Giannakis, Marios, Umeton, Renato, Manam, Monica Devi, Stover, Elizabeth H., Porter, Rebecca L., Johnson, Bruce E., Liaw, Kai-Li, Amonkar, Mayur, Church, Alanna J., Janeway, Katherine A., Nowak, Jonathan A., Sholl, Lynette, Lin, Nancy U., Johnson, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445788/
https://www.ncbi.nlm.nih.gov/pubmed/35050773
http://dx.doi.org/10.1200/PO.20.00185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445788/
https://www.ncbi.nlm.nih.gov/pubmed/35050773
http://dx.doi.org/10.1200/PO.20.00185

Ejemplares similares